Asian Spectator

Times Advertising

AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance

HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - AIM Vaccine (06660.HK) has added good news to the research and development of its heavyweight single product. According to the announcement on December 19, the clinical trial approval for the Group's suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological route and second generation of highly-effective absorbed tetanus vaccine have been recently obtained from the National Medical Products Administration.

Magazine

Cuma ‘nyuci-ngepel’: Bagaimana bias gender melanggengkan eksploitasi PRT di Indonesia

Aksi protes mendukung pengesahan UU PPRT di depan gedung DPR RI(Bagus upc/Shutterstock)● Kelas menengah Indonesia amat tergantung pada pekerja rumah tangga untuk mendukung produktivitas.● ...

Apakah gambar ‘Yesus’ Trump termasuk penistaan agama? Begini penjelasan ahli religi

Belum lama ini, Presiden Amerika Serikat (AS) Donald Trump mengunggah sebuah gambar hasil kecerdasan imitasi (AI). Gambar ini menampilkan dirinya mengenakan jubah putih, sembari meletakkan tangan yang...

Menguji kepemimpinan Prabowo: Kenapa mental sipil cendekia lebih dibutuhkan dibandingkan militer

Foto Presiden Prabowo Subianto dipajang dalam pigura foto di pasar tradisional di Bandung.SR_foto/Shutterstock● Memimpin negara butuh kapasitas intelektual dan moral yang kuat.● Mentalitas...